Stock 9969 INNOCARE PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 EDT 		5-day change 1st Jan Change
4.45 HKD +1.37% Intraday chart for InnoCare Pharma Limited +9.61% -35.41%
03-29 InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib CI
03-28 Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
CI
Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
CI
InnoCare to Shrink Loss in 2023
MT
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023
CI
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
CI
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program
CI
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
CI
Transcript : InnoCare Pharma Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:30 AM
InnoCare Elects CFO
MT
InnoCare Pharma Provides Results of Phase 2 Trial for Atopic Dermatitis Medication; Shares Rise 4%
MT
InnoCare Pharma Appoints Xin Fu as Chief Financial Officer
CI
InnoCare Pharma Limited Announces the Positive Top-Line Results from the Phase II Randomized, Double-Blind, Placebo-Controlled Study of ICP-332
CI
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH
CI
InnoCare Pharma Logs 109 Million Yuan Loss in Q3
MT
InnoCare Pharma Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
CI
Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director
CI
RemeGen Names CFO
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9969 Stock
  4. News InnoCare Pharma Limited